Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Marinomed Biotech stock price, quote, forecast and news

MARI.VI
ATMARINOMED6
A2N9MM

Price

5.40
Today +/-
+0.20
Today %
+3.77 %
P

Marinomed Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Marinomed Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Marinomed Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Marinomed Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Marinomed Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Marinomed Biotech Stock Price History

DateMarinomed Biotech Price
9/6/20245.40 undefined
9/5/20245.20 undefined
9/4/20245.42 undefined
9/3/20245.42 undefined
9/2/20245.46 undefined
8/30/20245.10 undefined
8/29/20245.30 undefined
8/28/20245.50 undefined
8/27/20245.50 undefined
8/26/20245.60 undefined
8/23/20245.66 undefined
8/22/20244.84 undefined
8/21/20244.90 undefined
8/20/20244.90 undefined
8/19/20245.20 undefined
8/16/20246.00 undefined
8/15/20245.00 undefined
8/14/20246.00 undefined
8/13/202410.05 undefined
8/12/202410.00 undefined

Marinomed Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Marinomed Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Marinomed Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Marinomed Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Marinomed Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Marinomed Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Marinomed Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Marinomed Biotech’s growth potential.

Marinomed Biotech Revenue, EBIT and net profit per share

DateMarinomed Biotech RevenueMarinomed Biotech EBITMarinomed Biotech Net Income
2029e53.66 M undefined0 undefined6.95 M undefined
2028e87.37 M undefined16.89 M undefined5.03 M undefined
2027e36.52 M undefined13.43 M undefined5.17 M undefined
2026e30.67 M undefined8.43 M undefined2.67 M undefined
2025e31.42 M undefined10.4 M undefined7.98 M undefined
2024e20.09 M undefined3.57 M undefined1.63 M undefined
20239.18 M undefined-5.13 M undefined-6.79 M undefined
202211.28 M undefined-4.91 M undefined-6.4 M undefined
202111.63 M undefined-4.14 M undefined-5.89 M undefined
20208.12 M undefined-5.82 M undefined-6.01 M undefined
20196.14 M undefined-6.21 M undefined-7.22 M undefined
20184.67 M undefined-5.14 M undefined-12.1 M undefined
20174.81 M undefined-1.64 M undefined-2.38 M undefined
20162.61 M undefined-1.51 M undefined-1.97 M undefined

Marinomed Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
2446811119203130368753
-100.00-50.0033.3337.50--18.18122.2255.00-3.2320.00141.67-39.08
-----9.0918.1811.11------
00000121000000
-1-1-5-6-5-4-4-5310813160
-50.00-25.00-125.00-100.00-62.50-36.36-36.36-55.5615.0032.2626.6736.1118.39-
-1-2-12-7-6-5-6-6172556
-100.00500.00-41.67-14.29-16.6720.00--116.67600.00-71.43150.00-20.00
1111.421.471.481.51.52000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Marinomed Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Marinomed Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
2.016.031.7212.029.215.88.182.59
0.841.190.621.482.333.41.391.4
0.50.420.911.682.851.411.730.98
0.050.180.120.10.931.031.561.01
00.040.360.050.081.241.411.15
3.47.853.7215.3415.412.8814.277.14
0.190.160.22.496.046.436.25.94
000350000
2.922.9112.8412.512.220.511.66.7
1.341.311.331.632.062.011.81.52
00000000
00000000
1.531.481.544.168.118.468.027.48
4.929.335.2619.523.521.3422.2914.61
               
0.130.1311.471.471.481.511.52
00000000
-2.78-5.16-17.279.43.88-1.29-5.66-11.66
000000-00
00000000
-2.65-5.03-16.2710.875.360.19-4.16-10.14
0.350.732.0111.981.991.151.53
75.1294.75118109101102.9119.4184.4
1.191.31.662.783.173.162.240.98
0131.18131.1800000
1.94.613.720.140.360.752.456.96
3.516.867.644.035.616.015.969.65
4.036.036.764.5112.4615.0420.1814.84
00000000
0.041.477.130.10.080.090.30.25
4.077.4913.894.6112.5415.1320.4915.09
7.5714.3621.538.6418.1421.1526.4424.75
4.929.335.2619.523.521.3422.2914.61
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Marinomed Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Marinomed Biotech's financial health and stability.

Assets

Marinomed Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Marinomed Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Marinomed Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Marinomed Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-1-2-12-7-6-5-6
0000000
0000000
000-2-1-10
0061011
0000000
0000000
-2-2-4-7-6-4-5
000-2-300
000-2-300
0000000
0000000
16022727
0000000
16020827
----1.00---
0000000
-14-410-2-32
-2.64-2.34-4.54-9.98-10.85-5.79-5.43
0000000

Marinomed Biotech stock margins

The Marinomed Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Marinomed Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Marinomed Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Marinomed Biotech's sales revenue. A higher gross margin percentage indicates that the Marinomed Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Marinomed Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Marinomed Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Marinomed Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Marinomed Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Marinomed Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Marinomed Biotech Margin History

Marinomed Biotech Gross marginMarinomed Biotech Profit marginMarinomed Biotech EBIT marginMarinomed Biotech Profit margin
2029e12.45 %0 %12.95 %
2028e12.45 %19.32 %5.75 %
2027e12.45 %36.77 %14.15 %
2026e12.45 %27.49 %8.69 %
2025e12.45 %33.12 %25.4 %
2024e12.45 %17.77 %8.13 %
202312.45 %-55.85 %-73.99 %
202218.98 %-43.58 %-56.74 %
202112.25 %-35.64 %-50.67 %
2020-7.9 %-71.57 %-73.98 %
2019-8.34 %-101.07 %-117.45 %
2018-3.55 %-110.21 %-259.24 %
201713.54 %-34.04 %-49.43 %
20166.75 %-57.98 %-75.72 %

Marinomed Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Marinomed Biotech earnings per share therefore indicates how much revenue Marinomed Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Marinomed Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Marinomed Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Marinomed Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Marinomed Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Marinomed Biotech Revenue, EBIT and net profit per share

DateMarinomed Biotech Sales per ShareMarinomed Biotech EBIT per shareMarinomed Biotech Earnings per Share
2029e34.84 undefined0 undefined4.51 undefined
2028e56.74 undefined0 undefined3.26 undefined
2027e23.71 undefined0 undefined3.36 undefined
2026e19.92 undefined0 undefined1.73 undefined
2025e20.4 undefined0 undefined5.18 undefined
2024e13.05 undefined0 undefined1.06 undefined
20236.05 undefined-3.38 undefined-4.48 undefined
20227.52 undefined-3.28 undefined-4.27 undefined
20217.88 undefined-2.81 undefined-3.99 undefined
20205.52 undefined-3.95 undefined-4.09 undefined
20194.33 undefined-4.38 undefined-5.09 undefined
20184.67 undefined-5.14 undefined-12.1 undefined
20174.81 undefined-1.64 undefined-2.38 undefined
20162.61 undefined-1.51 undefined-1.97 undefined

Marinomed Biotech business model

Marinomed Biotech is one of the most popular companies on Eulerpool.com.

Marinomed Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Marinomed Biotech historical P/E ratio, EBIT, and P/S ratio.

Marinomed Biotech shares outstanding

The number of shares was Marinomed Biotech in 2023 — This indicates how many shares 1.518 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Marinomed Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Marinomed Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Marinomed Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Marinomed Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Marinomed Biotech.

Marinomed Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2019-1.07 -0.76  (29.04 %)2019 Q4
1

Marinomed Biotech list of shareholders

%
Name
Stocks
Change
Date
8.65909 % Erste Asset Management GmbH133,35002/29/2024
8.08909 % Unger (Hermann)124,57202/14/2024
7.89175 % Prieschl-Grassauer (Eva)121,53302/14/2024
7.89175 % Grassauer (Andreas)121,53302/14/2024
5.11981 % AL Sheikh (Abdulmohsen)78,84502/14/2024
5.11981 % AL Sheikh (Mohammed)78,84502/14/2024
5.02429 % LLB Invest Kapitalanlagegesellschaft m.b.H.77,37417,7784/15/2024
1.90260 % 3 Banken-Generali Investment-Gesellschaft mbH29,30010,1008/31/2023
0.79935 % Abdulmohsen (Al Sheikh) & Mohammed (AlSheikh)12,31006/5/2023
0.74351 % Sparkasse Oberösterreich Kapitalanlagegesellschaft mbH11,450012/31/2023
1
2

Most common questions regarding Marinomed Biotech

What is the P/E ratio of Marinomed Biotech 2024?

The Marinomed Biotech P/E ratio is 5.02.

What is the P/S ratio of Marinomed Biotech 2024?

The Marinomed Biotech P/S ratio is 0.41.

What is the AlleAktien quality score of Marinomed Biotech?

The AlleAktien quality score for Marinomed Biotech is 3/10.

What is the revenue of Marinomed Biotech 2024?

The expected Marinomed Biotech revenue is 20.09 M EUR.

How high is the profit of Marinomed Biotech 2024?

The expected Marinomed Biotech profit is 1.63 M EUR.

What is the business model of Marinomed Biotech

No history available for Marinomed Biotech.

What is the Marinomed Biotech dividend?

Marinomed Biotech pays a dividend of 0 EUR distributed over payouts per year.

How often does Marinomed Biotech pay dividends?

The dividend cannot currently be calculated for Marinomed Biotech or the company does not pay out a dividend.

What is the Marinomed Biotech ISIN?

The ISIN of Marinomed Biotech is ATMARINOMED6.

What is the Marinomed Biotech WKN?

The WKN of Marinomed Biotech is A2N9MM.

What is the Marinomed Biotech ticker?

The ticker of Marinomed Biotech is MARI.VI.

How much dividend does Marinomed Biotech pay?

Over the past 12 months, Marinomed Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Marinomed Biotech is expected to pay a dividend of 0 EUR.

What is the dividend yield of Marinomed Biotech?

The current dividend yield of Marinomed Biotech is .

When does Marinomed Biotech pay dividends?

Marinomed Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Marinomed Biotech?

Marinomed Biotech paid dividends every year for the past 0 years.

What is the dividend of Marinomed Biotech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Marinomed Biotech located?

Marinomed Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Marinomed Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Marinomed Biotech from 9/9/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Marinomed Biotech pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Marinomed Biotech in the year 2023?

In the year 2023, Marinomed Biotech distributed 0 EUR as dividends.

In which currency does Marinomed Biotech pay out the dividend?

The dividends of Marinomed Biotech are distributed in EUR.

All fundamentals about Marinomed Biotech

Our stock analysis for Marinomed Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Marinomed Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.